Dan joined BresMed in 2011 and became a Board member in 2019. Before joining BresMed, Dan worked in R&D for Takeda Europe, leading the pre-, peri- and post-launch health economics and outcomes research (HEOR) planning for diabetes and obesity compounds. At BresMed, he has led the development of cost-effectiveness models and health technology assessment (HTA) submissions – providing strategic guidance on HEOR and market access. Dan achieved a PhD investigating the dynamic impact of health difficulties in adolescence on the formation of valued abilities and skills. Dan works with the rest of the Board to develop and articulate the strategic direction of BresMed.
In his spare time Dan loves to explore, engaging with new people and places.
What Dan says about BresMed: “BresMed is a brilliant company to work for. The culture is full of enthusiasm and innovation – working together in the pursuit of excellence.”